Skip to main content

Table 2 Comparison between groups A and B according to clinical outcome and overall survival

From: Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

  Group A Group B p value
Average VAS score at the first week
 Mean ± standard deviation 3.9 ± 1 6.6 ± 0.7 < 0.001
 Median (minimum–maximum) 4 (3–6) 7 (6–8)
Fever days, n (%)
< 5 days 8 (38.1%) 2 (11.1%) 0.004
5–10 days 12 (57.1%) 7 (38.9%)
 > 10 days 1 (4.8%) 9 (50%)
Fever days, median (interquartile range) 5 (2) 10 (5) 0.003
Free-time-to-PES symptoms (days)
 Mean ± standard deviation 7.2 ± 3.6 14.5 ± 4.5 < 0.001
 Median (minimum–maximum) 6 (3–17) 14 (5–21)
Ascites occurrence, number of patients (%) 2 (13.3%) 3 (23.1%) 0.5
Frequency of ALT levels elevation
 At month 1 9 (60%) 12 (92.3%) 0.084 (FE)
 At month 3 7 (46.7%) 8 (61.5%) 0.431
Frequency of AST levels elevation
 At month 1 11 (73.3%) 8 (61.5%) 0.689 (FE)
 At month 3 11 (73.3%) 10 (76.9%) 1.000 (FE)
Frequency of total bilirubin levels elevation
 At month 1 5 (33.3%) 4 (30.8%) 1.000 (FE)
 At month 3 7 (46.7%) 6 (46.2%) 0.978
Frequency of INR levels elevation
 At month 1 2 (13.3%) 2 (15.4%) 1.000 (FE)
 At month 3 3 (20%) 2 (15.4%) 1.000 (FE)
  1. ALT Alanine aminotransferase, AST Aspartate aminotransferase, FE Fisher exact, INR International normalised ratio, PES Post-embolisation syndrome, VAS Visual analogue scale
\